Mirum Pharmaceuticals, Inc.
AZURE 1 & 4
Hepatitis Delta Virus
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for AZURE 1 & 4 in Hepatitis Delta Virus are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“AZURE 1 & 4, Phase 3 topline data expected H2 2026 (US registrational program)”